Cervical carcinoma is the third most common gynaecological malignancy in women. It typically occurs in women who are on average 45 years old at onset of the disease.
and race with advanced cervical cancer, FIGO staging (IIB -IVB), were selected between June 2010 and August 2011 by the Department of Oncology to participate in the study. The clinical criteria included biopsy-proven untreated cancer of the cervix that was suitable for chemoradiotherapy, using the FIGO staging classification of carcinoma of the cervix. Approval to perform the investigation was obtained from the Ethics Committee of the Faculty of Health Sciences (UFS). All subjects gave written informed consent.
MRI protocol
All examinations were done on a 1.5 Tesla MRI machine (GE Healthcare, Buckinghamshire, UK) using an 8-channel body coil. Axial and sagittal T2-weighted images and axial diffusion-weighted images were acquired. Imaging parameters for T2-weighted fast recovery fast spin echo (FRFSE) were the following: repetition time (TR) 4 225 -6 200 ms, echo time (TE) 15 -100 ms, echo train length 15 kHz, bandwidth 20.83 kHz, field of view (FOV) 22 cm, slice thickness 4 mm, gap 1 mm, number of excitations 4, matrix 256 x 256, and acquisition time 4 minutes. Once the tumour had been visualised on conventional T2-weighted imaging, diffusion-weighted images were obtained in the axial plane that contained the largest tumour cross-section, using b-values of 500 and 1 000 s/mm 2 . Imaging parameters for these were TR 5 200 ms, TE 69.3 ms, bandwidth 62.5 kHz, FOV 32 cm, slice thickness 6 mm, gap 0 mm, number of excitations 16, matrix 128 x 128, and acquisition time 5 minutes. All patients were imaged before commencement of chemoradiation therapy, after 2 weeks of therapy, and during the final week of therapy (either the 5th or 6th week), depending on the exact treatment protocol instituted by the Department of Oncology.
T2-weighted imaging in the sagittal and axial planes was used for localisation of the tumour, measurement of its dimensions and assessment of morphological response. The tumour size was calculated as maximum craniocaudal x transverse diameter (cm 2 ) and was expressed as a percentage decrease in tumour size according to the time protocol, as well as the mean from start to completion of treatment. ADC maps were created on a GE Advantage 4.1 workstation. A tumour region of interest (ROI) was manually drawn on the diffusion-weighted images by using the highest signal intensity areas within the tumour, avoiding reduced signal intensity areas which could indicate necrotic areas and potentially bias the results. The ROIs were then superimposed on the ADC maps and a mean ADC value (x 10 -3 mm 2 /s) was determined by the workstation. To assist in follow-up measurements, an anatomic pelvic bony point was located, such as the acetabular notch or symphysis pubis, at the level of the ROI and used as reference point on follow-up scans. ADC values were determined with b-values of 500 and 1 000 s/mm 2 , respectively. All measurements were expressed quantitatively and as a percentage change from the previous measurements. We evaluated results collectively, as well as in 2 groups comparing responders and non-responders. Responders were categorised as those patients with a decrease in tumour size of more than 30% at the end of treatment. Nonresponders were regarded as those patients in whom the tumour size either increased or decreased by less than 30% at the end of treatment.
Results
Twenty patients were initially included in the study. Patients' ages ranged from 30 to 80 years, with a mean of 60 years. All had advanced cervical cancer (FIGO staging IIB -IVB) and clinical indications for chemoradiotherapy. Data of 17 patients were included in the analysis, with 3 patients (numbers 6, 17 and 19) being excluded. One patient died before therapy could be completed. Two patients' MRI studies were unsuitable for evaluation owing to motion artefacts. Fig. 1 shows an example of the pelvic axial MRI of one of the patients.
On average, the ADC values increased during the study and tumour sizes decreased. The ADC values (calculated with b-values of 500 and 1 000 s/mm 2 ) and tumour sizes collected over the time of the study are shown in Table 1 .
During the first 14 days, the ADC values increased by a mean of 20% and 24% for b=500 s/mm 2 and b=1 000 s/mm 2 , respectively, while tumour sizes decreased by a mean of only 8%. These results are summarised in Table 2 .
The relationship between the mean ADC values and tumour sizes is reflected graphically in Fig. 2 , demonstrating the early detection of tumour response using ADC values compared with tumour sizes, where response was seen at a later stage in the treatment regime.
In only 2 (11.8%) patients did tumour size not decrease by the final week of treatment, and a further 3 (17.6%) patients' tumour size decreased by less than 30%. These 5 patients were considered to be non-responders in the analysis and were compared with the 12 (70.6%) responders in whom tumour sizes decreased by more than 30%. In general, the changes were larger in responders than in non-responders. Table 3 compares the ADC values and sizes of the responders and nonresponders.
Discussion
In 2000, Therasse et al. published a set of rules to evaluate tumour response (morphological) during treatment. [8] The most recent version (RECIST 1.1 [9] ) suggests that the functional methods for tumour response assessment include positron emission tomography (PET) and PET-computed tomography (PET-CT) using 18-fluorodeoxyglucose ( 18 FDG) as a tracer, and dynamic contrast-enhanced MRI and MR spectroscopy. DW-MRI has so far not been considered in RECIST 1.1. This MR technique as a cancer biomarker has been discussed at a meeting of the International Society for MR in Medicine (ISMRM) in 2008 and, since then, many reports have been published highlighting the potential of this promising new technique in cancer patients. In 1990, Chenevert et al. [10] established the initial use of this principle of DWI-MRI in the treatment of brain tumours and found that malignant tumours, owing to their high cellularity, have a restriction of water movement (diffusion) reflected by a low ADC value; and, when the tumours respond to treatment, the ADC value will increase (less restriction of water movement) because of a decrease in tumour cellularity owing to apoptotic cell death. This indication will appear well before changes in tumour volume. [11] /s). [12] At present, its use in female pelvic tumours, especially cervical cancers, is limited. [9] [10] [11] [12] [13] The ADC value is calculated after DW-MRI that derives its contrast from the diffusion of water molecules (Brownian motion) within tumour tissue. Cell lysis is often the first effect of many different types of therapy, and theoretically this would lead to an increase in water diffusion, and therefore an increased ADC value. DW-MRI essentially involves T2-weighted MRI sequences during which a dephasing gradient is applied, followed a short while later by a rephasing gradient. Water molecules without any significant motion would not lose any signal apart from normal T2 decay. However, if significant motion of a molecule occurred, it would lose signal owing to the dephasing gradient, and not regain this signal with the rephasing gradient, as it would have moved from its original position. A b-value is assigned to DW-MRI, which effectively is a measurement of the size and duration of the dephasing gradient. A DW-MRI image with increased signal indicates restricted diffusion or possible T2 shine-through. Post-processing of this image yields an ADC map where low signal indicates restricted diffusion, whereas areas with T2 shine-through would remain high.
Our results indicate that an increase in ADC values for cervical carcinoma can be observed after treatment with chemoradiation. During the course of the study, we saw a mean decrease of 42% in tumour size, which correlated with a mean increase in ADC values of 35% (b=500 s/mm 2 ) and 43% (b=1 000 s/mm 2 ), respectively. This finding suggests that ADC measurement can be used in the evaluation of cervical carcinoma tumour response. /s with a b-value of 1 000 s/mm. [2, 14] We are of the opinion, however, that insufficient data are available to determine exact cut-off ADC values at the end of treatment for clinical practice, and further studies are necessary. The most significant observation was seen when evaluating the ADC and size values 14 days after treatment was commenced. of 500 and 1 000 s/mm 2 , respectively. During this time, the tumour size decreased by only 8% on conventional T2-weighted MRI. These findings were reversed for the period from 14 days to the last week of treatment, with the mean ADC value increasing by 13% (b=500 s/mm 2 ) and 15% (b=1 000 s/mm 2 ), respectively, and a relatively larger decrease in tumour size of 32%. These results indicate that ADC values will give an earlier indication of tumour response compared with tumour size, consistent with the pathophysiological principle of cell apoptosis during tumour response to treatment.
When considering those patients with >30% decrease in size after treatment as responders, we found that the responders had an initial mean ADC value of 1.26 x 10 -3 mm /s (b=1 000 s/mm 2 ). At both these b-values, the difference was statistically significant (p<0.05). In the same patients, the mean tumour size decreased from 23.83 cm 2 to 21.25 cm 2 over a period of 2 weeks. This decrease in tumour size was not statistically significant (p=0.075). At the end of treatment, however, the tumour size in the group of responders decreased to a mean of 10.26 cm 2 , which was statistically significant (p<0.05). The change in ADC value was statistically significant for all measurements in these patients. In the group of non-responders, the change in both ADC value and tumour size was not statistically significant at any stage. Regarding the ideal b-value to use, there is no universal consensus. In our study, the mean ADC values obtained during the time protocol of the study did not show a marked difference between the two b-values of 500 and 1 000 s/mm 2 . Thoeny and Ross, however, suggested using a moderate b-value (100 -600 s/mm 2 ) due to its effect to minimise the vascular signal of perfusion. [15] Other authors [16] [17] [18] recommended the use of high b-values (1 000 s/mm²), as it provides a more accurate measurement of water diffusion free of vascular contamination, as well as a low b-value (100 -600 s/mm 2 ) for better tumour visualisation to distinguish the lesions from normal anatomy. [16] [17] [18] We agree with the latter recommendation of using a minimum of two b-values to quantify ADC.
Conclusion
The study shows considerable promise in the use of ADC values to evaluate treatment response of cervical carcinoma, especially in detecting early response after 14 days of treatment. This non-invasive, non-contrast and non-ionising radiation, functional imaging technique might in future contribute to more advances in oncological therapy. 
